SCHOTT Pharma AG & Co KgaA (1SXP)

Currency in EUR
21.30
-1.10(-4.91%)
Closed·
Advertisement

SCHOTT Pharma (1SXP) Earnings Dates & Reports

Latest Release
13/05/2026
EPS / Forecast
0.21 / 0.21
Revenue / Forecast
248M / 245.73M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2026--/0.255--/272.03M----Free Sign Up
03/20260.210/0.211248.00M/245.73M-0.28%+0.92%Free Sign Up
12/20250.220/0.168240.19M/223.13M+30.95%+7.65%Free Sign Up
09/20250.221/0.235247.61M/248.32M-5.87%-0.29%Free Sign Up
06/20250.300/0.288256.46M/266.52M+4.13%-3.77%Free Sign Up
03/20250.260/0.217252.00M/240.25M+19.71%+4.89%Free Sign Up
12/20240.190/0.273230.00M/255.22M-30.38%-9.88%Free Sign Up
09/20240.228/0.163237.00M/259.71M+40.01%-8.74%Free Sign Up
06/20240.304/0.270253.74M/244.83M+12.44%+3.64%Free Sign Up
03/20240.166/0.170234.05M/234.05M-2.24%0%Free Sign Up

All numbers in EUR

SCHOTT Pharma AG & Co KgaA Earnings Call Summary for Q3/2026

  • Q3 revenue hit EUR 282M, beating forecast by EUR 10M; full-year growth guidance raised to 5%-6% from 2%-5% on broad-based demand improvement.
  • EBITDA margin fell to 26.8% from 32.3% year-over-year; full-year margin guidance lifted to 27%-28% with Q4 step-up expected despite profitability pressure.
  • High-value solutions reached 59% of Q3 revenue, nearing 60% midterm target; free cash flow surged 49% year-over-year to EUR 58.9M for nine months.
  • EUR 15M one-time glass syringe contract benefit to support 2026 growth but create 2027 headwind; capex expected at EUR 140-160M in 2026, rising in 2027.
  • Stock declined 1.12% to $22.15 despite beat; shares up 49% year-to-date but remain 8.1% below 52-week high amid margin concerns and elevated expectations.
Last Updated: 12/08/2026, 10:54
Read Full Transcript

FAQ

What Is SCHOTT Pharma's Earnings Per Share (TTM)?

The SCHOTT Pharma EPS for trailing twelve months (TTM) is 0.95.

When Is The Next SCHOTT Pharma (1SXP) Earnings Date?

SCHOTT Pharma will release its next earnings report on 12/08/2026, according to their financial calendar.

What Is SCHOTT Pharma’s Revenue Forecasts For Upcoming Quarters?

SCHOTT Pharma’s revenue forecast is 265.37M.

How Did SCHOTT Pharma Share Price React to the Company's Latest Earnings Report Results?

SCHOTT Pharma reported a -0.28% EPS surprise and a +0.92% revenue surprise, when comparing the latest 1SXP earnings report against analyst forecasts. The stock price changed by 5.48%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.